Alcohol detox for Delray Beach — CIWA-Ar-guided, medically supervised, discretion assured.

RECO Island's detox unit at 140 NE 4th Avenue is 0 minutes from every Delray Beach neighborhood — Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, Osceola Park — and connects directly to on-campus residential treatment without a third-party handoff or waitlist. Alcohol withdrawal is CIWA-Ar-scored around the clock with symptom-triggered benzodiazepine dosing, parenteral thiamine, and physician oversight from admission through transition. Small census, in-house medical team, and continuity between detox and residential are the reason clients from Delray Beach admit here rather than route to a facility that discharges them after five days.

RECO Island’s Delray Beach campus at 140 NE 4th Avenue sits one block off Atlantic Avenue and a five-minute walk from the ocean. For residents of Pineapple Grove, Lake Ida, Tropic Isle, the Beach District, and Osceola Park, medical detox for alcohol use disorder happens inside the same square mile they already live in — not at a facility three counties away that requires uprooting the rest of a life to reach. The alcohol detox program is physician-led, nurse-staffed, and CIWA-Ar-scored, with direct in-house transition to residential treatment on the same campus.

Alcohol withdrawal is the one that can kill you

Unlike opioid or stimulant withdrawal — miserable but not lethal in an otherwise healthy adult — alcohol withdrawal carries a genuine mortality rate. Untreated severe withdrawal produces generalized tonic-clonic seizures, cardiovascular instability, and delirium tremens, which historically carried a mortality approaching 5-15% without medical management and remains meaningfully lethal even with treatment. Alcohol withdrawal is not a candidate for home management.

Risk stratification at intake identifies clients likely to progress to complicated withdrawal. The strongest predictor is a prior withdrawal seizure or DT episode — one prior event roughly triples the risk of the next. Additional risk factors include daily alcohol volume above roughly eight standard drinks, duration of heavy use greater than ten years, age over 40, concurrent benzodiazepine dependence, and medical comorbidities including hepatic disease, cardiac disease, and electrolyte derangement. Clients meeting high-risk criteria are staffed for closer nursing observation and lower CIWA-Ar treatment thresholds.

Medical detox for alcohol use disorder is not a preference or an amenity. It is the standard of care under ASAM Criteria dimensions 1 (acute intoxication and withdrawal potential) and 2 (biomedical conditions and complications), and it is what separates a survivable withdrawal from a preventable death.

CIWA-Ar and symptom-triggered benzodiazepine dosing

The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is a ten-domain scale scoring nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation. Scores range 0-67, with treatment thresholds typically triggered at 8-10 and higher scores prompting escalated dosing and closer monitoring. Nursing staff score CIWA-Ar every one to four hours depending on severity trajectory, with more frequent assessment for high-risk clients.

Benzodiazepines are the pharmacologic backbone of alcohol withdrawal management because they cross-taper the same GABA-A receptor system that alcohol dysregulates. Chlordiazepoxide is preferred for uncomplicated withdrawal in clients with intact hepatic function due to its long half-life and self-tapering pharmacokinetics. Lorazepam is used in clients with significant hepatic impairment because its metabolism does not depend on hepatic oxidation. Diazepam offers a rapid front-loading strategy for severe presentations.

Symptom-triggered dosing — administering benzodiazepines only when CIWA-Ar scores cross threshold — produces shorter treatment courses, lower total benzodiazepine exposure, and equivalent or superior safety outcomes compared with fixed-schedule dosing. It is the protocol supported by the most consistent evidence base and is standard at RECO Island.

Thiamine, folate, and Wernicke prevention

Chronic heavy alcohol use produces thiamine (vitamin B1) deficiency through inadequate dietary intake, impaired gastrointestinal absorption, and impaired hepatic storage. Untreated deficiency progresses to Wernicke’s encephalopathy — the classical triad is encephalopathy, oculomotor dysfunction, and gait ataxia, though the full triad is present in only about a third of cases — and if untreated further, to Korsakoff’s syndrome, an irreversible amnestic disorder.

Admission protocol at RECO Island includes parenteral thiamine 100 mg IM or IV on day one, continued for at least three days, with higher doses (500 mg IV three times daily) reserved for suspected Wernicke’s presentation. Oral thiamine absorption is unreliable in the withdrawal population, which is why the initial dose is parenteral. Folate, a multivitamin, and magnesium replacement are administered in parallel; magnesium deficiency lowers seizure threshold and impairs benzodiazepine efficacy.

Glucose administered before thiamine can precipitate Wernicke’s in a deficient client. This is why thiamine precedes any IV dextrose in the admission sequence — a small procedural detail with permanent neurologic consequences if reversed.

MAT initiation during detox and the transition to residential

Medication-assisted treatment for alcohol use disorder is FDA-approved in three agents: naltrexone (oral 50 mg daily or long-acting injectable Vivitrol 380 mg IM monthly), acamprosate (666 mg three times daily), and disulfiram (250 mg daily). Each has a distinct mechanism and clinical fit, and the choice is built into the treatment plan during detox rather than deferred to discharge.

Naltrexone, an opioid receptor antagonist, reduces the reinforcing effects of alcohol and the frequency of heavy drinking days. It requires a 7-10 day opioid-free window before initiation, which medical detox reliably provides. Acamprosate modulates glutamate and GABA signaling and is typically initiated near the end of the detox stay once abstinence is stabilized. Disulfiram — the aversive agent that produces a violent reaction with alcohol ingestion — is reserved for clients with strong motivation and reliable supervision.

Because detox and residential run under a single clinical team on one campus, MAT decisions made during detox carry seamlessly into residential treatment. There is no third-party handoff, no waitlist, no gap during which the client is asked to arrange their own transition.

What to expect on admission from Delray Beach

Admission begins with a physician H&P, nursing assessment, CIWA-Ar baseline score, and biopsychosocial intake. Laboratory workup includes CBC, comprehensive metabolic panel, magnesium, phosphate, GGT, PT/INR, urinalysis, and urine drug screen; ECG is obtained for clients over 40 or with cardiac history. PHQ-9 and GAD-7 are administered to screen for co-occurring depression and anxiety, which are present in a substantial majority of alcohol use disorder admissions and shape both the detox medication plan and the residential treatment plan.

Belongings are inventoried, a contraband search is completed, and the client is oriented to the unit and staff. Family contact preferences are established. Most Delray Beach clients arrive within an hour of the initial phone call — the campus is on the same side of town as every named neighborhood — and the intake team coordinates directly with anyone en route.

Insurance and admissions from Delray Beach

RECO Island works with most major commercial carriers relevant to Palm Beach County — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Verification of benefits is completed by the admissions team before intake, and the cost estimate — deductible, co-insurance, out-of-pocket maximum, and any pre-authorization requirements — is presented in writing before the client commits.

For Delray Beach residents, the campus at 140 NE 4th Avenue is 0 miles and 0 minutes away — treatment happens in the neighborhood, not across the state. The admissions line answers 24 hours a day, and same-day admission is available in the overwhelming majority of medically appropriate cases.

Serving residents of: Pineapple Grove, Lake Ida, Tropic Isle, Beach District, Osceola Park.